for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ビジネス

Not too late to buy Biogen -strategist

O'Neil Global Advisors Chief Investment Officer Randy Watts tells Reuters' Fred Katayama why he thinks Biogen shares aren't that pricey over the long term despite their 38% runup Monday on news of the approval of its Alzheimer's drug.

最新のビデオ
エンタテインメント
世界のこぼれ話
スポーツ
テクノロジー

ビジネス

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up